Auteur S. ASSI

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'

C. T. GALLAGHER ; S. ASSI ; J. L. STAIR ; S. FERGUS ; O. CORAZZA ; J. M. CORKERY ; F. SCHIFANO | 2012
Dans Human Psychopharmacology: Clinical and Experimental (Vol.27, n°2, March 2012) Article : Périodique

OBJECTIVES: The fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the[...]

Plus d'info

Ajouter à la sélection

From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine

O. CORAZZA ; S. ASSI ; F. SCHIFANO | 2013
Dans CNS Neuroscience and Therapeutics (Vol.19, n°6, June 2013) Article : Périodique

This article reviews the recreational use of ketamine ("Special K"; KET) and explores the recent diffusion of its new derivative methoxetamine ("Special M"; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carri[...]

Plus d'info

Ajouter à la sélection

'In and Out of the Hole': An exploration on phencyclidine derivatives

A. NEGRI ; S. ASSI | 2019
Chapitre

Plus d'info

Ajouter à la sélection

Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages

O. CORAZZA ; S. ASSI ; S. MALEKIANRAGHEB ; M. N. BENI ; I. BIGDELI ; Z. ASLANPOUR ; F. SCHIFANO | 2014
Dans International Journal of Drug Policy (Vol.25, n°4, July 2014) Article : Périodique

Background: Numbers of novel psychoactive substances (NPS) have been rapidly increasing over the past few years, with unprecedented challenges on traditional drug control systems. The web has been involved in the promotion and knowledge dissemin[...]

Plus d'info

Ajouter à la sélection

Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine

O. CORAZZA ; F. SCHIFANO ; P. SIMONATO ; S. FERGUS ; S. ASSI ; J. L. STAIR ; J. CORKERY ; G. TRINCAS ; P. DELUCA ; Z. DAVEY ; U. BLASZKO ; Z. DEMETROVICS ; J. MOSKALEWICZ ; A. ENEA ; G. DI MELCHIORRE ; B. MERVO ; L. DI FURIA ; M. FARRE ; L. H. FLESLAND ; M. PASINETTI ; C. PEZZOLESI ; A. PISARSKA ; H. SHAPIRO ; H. SIEMANN ; A. SKUTLE ; E. SFERRAZZA ; M. TORRENS ; P. VAN DER KREEFT ; D. ZUMMO ; N. SCHERBAUM | 2012
Dans Human Psychopharmacology: Clinical and Experimental (Vol.27, n°2, March 2012) Article : Périodique

On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to [...]

Plus d'info

Ajouter à la sélection

Uses, effects and toxicity of synthetic cannabinoids from the perspective of people with lived experiences

S. ASSI ; D. MARSHALL ; F. S. BERSANI ; O. CORAZZA | 2020
Dans Journal of Psychoactive Drugs (Vol.52, n°3, July-August 2020) Article : Périodique

Synthetic cannabinoids (SCs) are a class of synthetic chemicals with cannabis-like properties, and little is known about their pharmacological and toxicological effects. The objective of this study was to explore the effects of SCs and the under[...]

Plus d'info

Ajouter à la sélection

Lien externe